New drug combo targets tough ovarian cancers
NCT ID NCT06617923
Summary
This study is testing whether two drugs, Senaparib and Temozolomide, work together to shrink tumors in women with recurrent clear cell or endometrioid ovarian, fallopian tube, or primary peritoneal cancers that have a specific genetic change called an ARID1A mutation. The trial is for adult women whose cancer has come back after at least two prior treatments or who have platinum-resistant disease. Participants will take both drugs daily in repeating 28-day cycles while doctors monitor their response and check for side effects.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for FALLOPIAN TUBE CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
RECRUITINGBaltimore, Maryland, 21231-2410, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
University of Pennsylvania/Abramson Cancer Center
RECRUITINGPhiladelphia, Pennsylvania, 19104, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.